QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of the Microbiome WGS SeqSets, a comprehensive Sample to
Insight workflow designed to provide an easy-to-use solution that
maximizes efficiency and reproducibility in microbiome research.
The workflow streamlines the process steps
involving sample extraction and next-generation sequencing (NGS)
library preparation to prepare the sample for processing in an NGS
sequencer, followed by user‑friendly bioinformatics analysis
designed for researchers without expertise in the field.
Gaining prominence in recent years, microbiome
research explores the relationships between microorganisms such as
bacteria, fungi and viruses, and their hosts. The goal is to better
understand their impact on health, diseases and ecological
processes in order to develop novel diagnostic and therapeutic
strategies.
“Our Microbiome WGS SeqSets provide a complete
Sample to Insight solution that combines our industry-leading
extraction technology with easy-to-use downstream NGS library
preparation and intuitive bioinformatics. This streamlined workflow
addresses challenges such as DNA extraction bias, library
preparation complexity, and bioinformatics expertise, allowing
researchers to focus on their scientific discoveries while we
enable a smooth and reliable process,” said Nitin Sood, Senior Vice
President and Head of the Life Sciences Business Area at
QIAGEN.
The QIAamp PowerFecal Pro WGS SeqSets and the
DNeasy PowerSoil Pro WGS SeqSets offer unified solutions for gut
and soil samples. The workflow begins with DNA extraction using the
DNeasy PowerSoil Pro or QIAamp PowerFecal Pro DNA Kits, which
efficiently isolate high yields of DNA and identify greater
bacterial diversity than other commercial kits.
Following extraction, the QIAseq Normalizer Kit
streamlines library normalization, enabling easy pooling for
high-throughput sequencing. The QIAseq FX DNA Library Kit enables
rapid 2.5-hour NGS library preparation for whole genome metagenomic
analysis, creating sequencing libraries with minimal bias through
enzymatic fragmentation and adapter ligation. “We recommend the
QIAseq FX DNA Library Kit for taxonomic profiling based on its high
accuracy, low GC bias, and excellent transferability across
laboratories,” said Dr. Dieter M. Tourlousse, Senior Scientist at
the National Institute of Advanced Industrial Science and
Technology (AIST) in Japan.
Finally, bioinformatics analysis is conducted
using the Microbial Analysis Portal, an intuitive web-based
platform. It enables taxonomic identification of microbes, provides
a detailed breakdown of microbial species, and supports
antimicrobial resistance (AMR) analysis for identifying antibiotic
resistance genes. Users can easily and quickly generate
publication-ready data and figures.
The SeqSets are designed for diverse microbiome
research applications, including studies of gut health, soil
microbiology, antibiotic resistance, and many others.
The new workflow further expands the growing
portfolio of QIAGEN microbiome solutions. In true Sample to Insight
spirit, the comprehensive portfolio encompasses tools for every
aspect of the scientific workflow, including reliable sample
preparation kits optimized for investigating challenging samples
from environmental and human microbiomes. To ensure
reproducibility, QIAGEN offers sample preparation automation for
standardization and reliability. The extensive range of microbiome
solutions also includes downstream processing technologies such as
NGS, digital PCR (dPCR), or quantitative PCR (qPCR), all
complemented by robust bioinformatics tools for seamless digital
analysis.
More information on the Sample to Insight
workflow for microbiome researchers can be found here:
https://www.qiagen.com/applications/microbiome/workflow
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
September 30, 2023, QIAGEN employed more than 6,000 people in
over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024